Prostate cancer drug study halted before starting
NCT ID NCT03274778
Summary
This study aimed to learn how a drug called ruxolitinib changes immune cells inside prostate tumors. Men scheduled for prostate cancer surgery would have taken the drug for four weeks before their operation. Researchers planned to analyze tumor and blood samples to see how the drug worked, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.